On Nov 05, major Wall Street analysts update their ratings for $Owens & Minor (OMI.US)$, with price targets ranging from $12.5 to $18.5.
BofA Securities analyst Allen Lutz maintains with a sell rating, and adjusts the target price from $16 to $12.5.
Citi analyst Daniel Grosslight maintains with a buy rating, and sets the target price at $18.5.
Barclays analyst Stephanie Davis maintains with a hold rating, and adjusts the target price from $18 to $14.
Baird analyst Eric Coldwell maintains with a hold rating, and adjusts the target price from $19 to $14.
Leerink Partners analyst Michael Cherny maintains with a hold rating, and adjusts the target price from $17 to $14.
Furthermore, according to the comprehensive report, the opinions of $Owens & Minor (OMI.US)$'s main analysts recently are as follows:
The company's Q3 results demonstrated a varied performance, with revenue matching expectations but segment profitability showing fluctuations. The company is persistently addressing its eligibility backlog which arose following the Change hack.
The company's third-quarter performance exceeded expectations but was counterbalanced by a reduction in profitability forecasts for fiscal 2024 and a negative free cash flow projection.
The company's recent quarter results showcased robust EBIT growth in its Patient Direct sector, which was somewhat offset by underperformance in Product & Health Services. The standout feature of the quarter was the notable operating margin in Patient Direct. However, there's growing concern regarding margin pressures within medical distribution, raising further questions about competitive movements in that area. This leads to a more cautious stance concerning the margin outlook leading up to 2025.
The assessment of Owens & Minor's third quarter performance indicated it met expectations with minimal surprises, and the initial negative reaction in the stock market was deemed excessive. The fourth quarter is anticipated to face challenges due to the residual impacts of hurricane activity on the company's PHS segment, which is likely to be somewhat balanced by a more robust Patient Direct segment. Additionally, cash flow is projected to experience a sequential improvement.
Here are the latest investment ratings and price targets for $Owens & Minor (OMI.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月5日，多家華爾街大行更新了$歐麥斯-麥能醫療 (OMI.US)$的評級，目標價介於12.5美元至18.5美元。
美銀證券分析師Allen Lutz維持賣出評級，並將目標價從16美元下調至12.5美元。
花旗分析師Daniel Grosslight維持買入評級，目標價18.5美元。
巴克萊銀行分析師Stephanie Davis維持持有評級，並將目標價從18美元下調至14美元。
貝雅分析師Eric Coldwell維持持有評級，並將目標價從19美元下調至14美元。
Leerink Partners分析師Michael Cherny維持持有評級，並將目標價從17美元下調至14美元。
此外，綜合報道，$歐麥斯-麥能醫療 (OMI.US)$近期主要分析師觀點如下：
公司的第三季度業績表現多種多樣，營業收入符合預期，但板塊盈利能力出現波動。該公司正在堅決解決由Change黑客襲擊後出現的資格積壓問題。
公司的第三季度表現超出預期，但卻被2024財年盈利預測下調以及負面自由現金流預測所抵消。
公司最近一個季度的業績展示了其患者直銷板塊的強勁EBIt增長，但在產品與健康服務方面表現不佳。該季度的亮點是患者直銷領域顯着的營業利潤率。然而，醫療分配中的利潤壓力日益引起關注，進一步提出了關於該領域競爭動態的疑問。這導致對2025年營業利潤率前景更爲謹慎。
對Owens & Minor第三季度業績的評估表明符合預期，沒有太多意外，並且股市初期的負面反應被認爲過度。預期第四季度將面臨挑戰，原因是颶風活動對公司PHS板塊的殘留影響，但這可能會在更強勁的患者直銷板塊中得到一定平衡。此外，預計現金流將出現順序性改善。
以下爲今日5位分析師對$歐麥斯-麥能醫療 (OMI.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
